WallStSmart

Addex Therapeutics Ltd (ADXN)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 60062002% more annual revenue ($65.77B vs $109,500). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).

ADXN

Avoid

20

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 4.0
Piotroski: 1/9Altman Z: -80.94

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ADXN.

MRKSignificantly Overvalued (-62.3%)

Margin of Safety

-62.3%

Fair Value

$81.23

Current Price

$129.79

$48.56 premium

UndervaluedFair: $81.23Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ADXN2 strengths · Avg: 10.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$307.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

ADXN4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.46M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ADXN

The strongest argument for ADXN centers on Price/Book, Debt/Equity.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : ADXN

The primary concerns for ADXN are EPS Growth, Market Cap, Profit Margin.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

ADXN carries more volatility with a beta of 1.99 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 20/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Addex Therapeutics Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Addex Therapeutics Ltd, a developing-stage biopharmaceutical company, discovers, develops and markets small molecule pharmaceuticals for central nervous system (CNS) disorders in Switzerland. The company is headquartered in Geneva, Switzerland.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?